Literature DB >> 11330883

Celiprolol stimulates endothelial nitric oxide synthase expression and improves myocardial remodeling in deoxycorticosterone acetate-salt hypertensive rats.

N Kobayashi1, Y Mori, S Nakano, Y Tsubokou, H Shirataki, H Matsuoka.   

Abstract

OBJECTIVE: Endothelium-dependent vasodilation is attenuated in humans and experimental hypertension models, and this phenomenon may be largely due to decreased release or activity of nitric oxide (NO). However, very few studies have evaluated whether beta-adrenoceptor antagonists increase endothelial NO synthase (eNOS) expression in the left ventricle. We examined the effects of long-term treatment with celiprolol, a specific beta1-antagonist with a weak beta2-agonist action, on eNOS expression in the left ventricle and evaluated its relationship to myocardial remodeling in the left ventricle of deoxycorticosterone acetate (DOCA)-salt hypertensive rats.
METHODS: DOCA-salt rats (n = 18) were induced with weekly injections of DOCA (30 mg/kg) and 1% saline in their drinking water after right nephrectomy. Celiprolol (DOCA-CEL, n = 9, 10 mg/kg per day, subdepressor dose) or a vehicle (DOCA-V, n = 9) were given after induction of DOCA-salt hypertension for 5 weeks, and age-matched sham-operated rats (ShC, n = 9) served as a control group.
RESULTS: Blood pressure levels in DOCA-V and DOCA-CEL were similar and significantly higher than that in ShC. The eNOS mRNA and protein levels, and NOS activity in the left ventricle significantly decreased in DOCA-V compared with ShC, and significantly increased in DOCA-CEL compared with DOCA-V. DOCA-V showed a significant increase in the wall-to-lumen ratio, perivascular fibrosis, myocardial fibrosis, and type I collagen mRNA, with all these parameters being significantly improved by celiprolol.
CONCLUSIONS: Myocardial remodeling of DOCA-salt hypertensive rats was significantly ameliorated by subdepressor doses of celiprolol, which may be due to increased eNOS expression in the left ventricle.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11330883     DOI: 10.1097/00004872-200104000-00017

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

1.  Pharmacological evidence: a new therapeutic approach to the treatment of chronic heart failure through SUR2B/Kir6.1 channel in endothelial cells.

Authors:  Shang Wang; Chao-Liang Long; Jun Chen; Wen-Yu Cui; Yan-Fang Zhang; Hao Zhang; Hai Wang
Journal:  Acta Pharmacol Sin       Date:  2016-11-28       Impact factor: 6.150

Review 2.  Extracellular matrix fibrotic markers in heart failure.

Authors:  Faiez Zannad; Patrick Rossignol; Wafae Iraqi
Journal:  Heart Fail Rev       Date:  2010-07       Impact factor: 4.214

Review 3.  Cardioprotective mechanisms of lifestyle modifications and pharmacotherapies on cardiac remodeling and dysfunction in hypertensive heart disease: an overview.

Authors:  Kohzo Nagata; Takuya Hattori
Journal:  Nagoya J Med Sci       Date:  2011-08       Impact factor: 1.131

Review 4.  Molecules and Mechanisms to Overcome Oxidative Stress Inducing Cardiovascular Disease in Cancer Patients.

Authors:  Francesco Sabbatino; Valeria Conti; Luigi Liguori; Giovanna Polcaro; Graziamaria Corbi; Valentina Manzo; Vincenzo Tortora; Chiara Carlomagno; Carmine Vecchione; Amelia Filippelli; Stefano Pepe
Journal:  Life (Basel)       Date:  2021-01-30

5.  The effects of 17-methoxyl-7-hydroxy-benzene-furanchalcone on the pressure overload-induced progression of cardiac hypertrophy to cardiac failure.

Authors:  Jianchun Huang; XiaoJun Tang; Xingmei Liang; Qingwei Wen; Shijun Zhang; Feifei Xuan; Jie Jian; Xing Lin; Renbin Huang
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.752

Review 6.  The Antioxidant Therapy: New Insights in the Treatment of Hypertension.

Authors:  Daniela Sorriento; Nicola De Luca; Bruno Trimarco; Guido Iaccarino
Journal:  Front Physiol       Date:  2018-03-21       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.